Bone Therapeutics More Interested In A Partner Than A Buyer
As Hybrigenics Pushes For Merger
Miguel Forte, Bone Therapeutics CEO, has told Scrip that another approach from French company Hybrigenics about a merger came as a surprise, adding that his priority is the expansion of the Belgian biotech's allogenic cell therapy platform after the recent failure of its Phase III asset for knee osteoarthritis pain.
You may also be interested in...
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.